Marianne Harris

Summary

Affiliation: British Columbia
Country: Canada

Publications

  1. ncbi Nephrotoxicity associated with antiretroviral therapy in HIV-infected patients
    Marianne Harris
    Expert Opin Drug Saf 7:389-400. 2008
  2. ncbi Enfuvirtide plasma levels and injection site reactions using a needle-free gas-powered injection system (Biojector)
    Marianne Harris
    British Columbia Centre for Excellence in HIV AIDS, Vancouver, British Columbia, Canada
    AIDS 20:719-23. 2006
  3. ncbi Outcomes of multidrug-resistant patients switched from enfuvirtide to raltegravir within a virologically suppressive regimen
    Marianne Harris
    AIDS Research Programme, St Paul s Hospital, Providence Healthcare, Canada
    AIDS 22:1224-6. 2008
  4. ncbi Exploring mitochondrial nephrotoxicity as a potential mechanism of kidney dysfunction among HIV-infected patients on highly active antiretroviral therapy
    Helene C F Cote
    British Columbia Centre for Excellence in HIV AIDS, Providence Health Care, Vancouver, BC, Canada
    Antivir Ther 11:79-86. 2006
  5. ncbi Nucleoside-related mitochondrial toxicity among HIV-infected patients receiving antiretroviral therapy: insights from the evaluation of venous lactic acid and peripheral blood mitochondrial DNA
    Julio S G Montaner
    BC Centre for Excellence in HIV AIDS and the Canadian HIV Trials Network, St Paul s Hospital, Providence Health Care, University of British Columbia, Vancouver, Canada
    Clin Infect Dis 38:S73-9. 2004
  6. ncbi Lopinavir/ritonavir pharmacokinetics in a substitution of high-dose soft-gelatin capsule to tablet formulation
    Mark W Hull
    Canadian HIV Trials Network, Vancouver, Canada
    J Clin Pharmacol 49:155-61. 2009
  7. ncbi Management of HIV-infected patients with multidrug-resistant virus
    Marianne Harris
    British Columbia Centre for Excellence in HIV/AIDS, Providence Health Care/University of British Columbia, 667-1081 Burrard Street, Vancouver, BC V6Z 1Y6, Canada
    Curr HIV/AIDS Rep 1:116-21. 2004
  8. ncbi Treatment interruption of highly active antiretroviral therapy in patients with nadir CD4 cell counts >200 cells/mm3
    Adrienne R Toulson
    BC Centre for Excellence in HIV/AIDS, Faculty of Medicine, University of British Columbia, Vancouver, Canada
    J Infect Dis 192:1787-93. 2005
  9. ncbi A comparison of the predictive performance of different methods of kidney function estimation in a well-characterized HIV-infected population
    Katherine Barraclough
    Division of Nephrology, University of British Columbia, Vancouver, B C, Canada
    Nephron Clin Pract 111:c39-48. 2009
  10. ncbi Mitochondrial toxicity in the era of HAART: evaluating venous lactate and peripheral blood mitochondrial DNA in HIV-infected patients taking antiretroviral therapy
    Julio S G Montaner
    British Columbia Centrefor Excellence in HIV AIDS and the Canadian HIV Trials Network, St Paul s Hospital, Providence Health Care, University of British Columbia, Vancouver, Canada
    J Acquir Immune Defic Syndr 34:S85-90. 2003

Collaborators

Detail Information

Publications32

  1. ncbi Nephrotoxicity associated with antiretroviral therapy in HIV-infected patients
    Marianne Harris
    Expert Opin Drug Saf 7:389-400. 2008
    ..Some antiretroviral therapies have themselves been identified to have clinically significant nephrotoxicity...
  2. ncbi Enfuvirtide plasma levels and injection site reactions using a needle-free gas-powered injection system (Biojector)
    Marianne Harris
    British Columbia Centre for Excellence in HIV AIDS, Vancouver, British Columbia, Canada
    AIDS 20:719-23. 2006
    ....
  3. ncbi Outcomes of multidrug-resistant patients switched from enfuvirtide to raltegravir within a virologically suppressive regimen
    Marianne Harris
    AIDS Research Programme, St Paul s Hospital, Providence Healthcare, Canada
    AIDS 22:1224-6. 2008
    ..The new regimen was well tolerated with no apparent new drug-related adverse clinical or laboratory events...
  4. ncbi Exploring mitochondrial nephrotoxicity as a potential mechanism of kidney dysfunction among HIV-infected patients on highly active antiretroviral therapy
    Helene C F Cote
    British Columbia Centre for Excellence in HIV AIDS, Providence Health Care, Vancouver, BC, Canada
    Antivir Ther 11:79-86. 2006
    ..Mitochondrial nephrotoxicity was investigated as an underlying mechanism. Given the interaction between TDF and didanosine (ddl), their concurrent use was also investigated...
  5. ncbi Nucleoside-related mitochondrial toxicity among HIV-infected patients receiving antiretroviral therapy: insights from the evaluation of venous lactic acid and peripheral blood mitochondrial DNA
    Julio S G Montaner
    BC Centre for Excellence in HIV AIDS and the Canadian HIV Trials Network, St Paul s Hospital, Providence Health Care, University of British Columbia, Vancouver, Canada
    Clin Infect Dis 38:S73-9. 2004
    ..A statistically significant increase in the mtDNA : nDNA ratio was observed after the discontinuation of antiretroviral therapy. Full validation of monitoring the mtDNA : nDNA ratio is currently under way...
  6. ncbi Lopinavir/ritonavir pharmacokinetics in a substitution of high-dose soft-gelatin capsule to tablet formulation
    Mark W Hull
    Canadian HIV Trials Network, Vancouver, Canada
    J Clin Pharmacol 49:155-61. 2009
    ....
  7. ncbi Management of HIV-infected patients with multidrug-resistant virus
    Marianne Harris
    British Columbia Centre for Excellence in HIV/AIDS, Providence Health Care/University of British Columbia, 667-1081 Burrard Street, Vancouver, BC V6Z 1Y6, Canada
    Curr HIV/AIDS Rep 1:116-21. 2004
    ..Some new drugs are available that may be helpful if used carefully with an active background regimen...
  8. ncbi Treatment interruption of highly active antiretroviral therapy in patients with nadir CD4 cell counts >200 cells/mm3
    Adrienne R Toulson
    BC Centre for Excellence in HIV/AIDS, Faculty of Medicine, University of British Columbia, Vancouver, Canada
    J Infect Dis 192:1787-93. 2005
    ..A nadir CD4 cell count of 200-250 cells/mm(3) and the 11/25 viral genotype were found to be associated with a faster HAART reinitiation...
  9. ncbi A comparison of the predictive performance of different methods of kidney function estimation in a well-characterized HIV-infected population
    Katherine Barraclough
    Division of Nephrology, University of British Columbia, Vancouver, B C, Canada
    Nephron Clin Pract 111:c39-48. 2009
    ..Glomerular filtration rate (GFR) estimation equations have never been validated in the HIV population. This pilot study aimed to compare all currently available methods of kidney function assessment with nuclear GFR in HIV-infected adults...
  10. ncbi Mitochondrial toxicity in the era of HAART: evaluating venous lactate and peripheral blood mitochondrial DNA in HIV-infected patients taking antiretroviral therapy
    Julio S G Montaner
    British Columbia Centrefor Excellence in HIV AIDS and the Canadian HIV Trials Network, St Paul s Hospital, Providence Health Care, University of British Columbia, Vancouver, Canada
    J Acquir Immune Defic Syndr 34:S85-90. 2003
    ..These results suggest that measurement of this parameter should be investigated as a potential clinical management tool...
  11. ncbi Rates of disease progression among human immunodeficiency virus-infected persons initiating multiple-drug rescue therapy
    Nelson Lee
    British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada
    J Infect Dis 188:137-41. 2003
    ..Over the short-term, patients receiving MDRT had relatively low mortality. After adjustment for baseline prognostic factors, rates of survival were comparable with those in patients initiating triple-drug ART...
  12. ncbi Simplification of therapeutic drug monitoring for twice-daily regimens of lopinavir/ritonavir for HIV infection
    Christopher S Alexander
    British Columbia Centre for Excellence in HIV AIDS, Vancouver, British Columbia, Canada
    Ther Drug Monit 26:516-23. 2004
    ..Evening trough concentrations were the best estimators of the daily nadir; however, no adequate substitute for collecting blood 12 hours postdose emerged from this analysis...
  13. ncbi An unusual case of acute kidney injury due to vancomycin lessons learnt from reliance on eGFR
    Katherine Barraclough
    Department of Nephrology, St Paul s Hospital, Vancouver, British Colombia, V6Z1Y6, Canada
    Nephrol Dial Transplant 22:2391-4. 2007
    ..We support ongoing efforts to develop or refine equations for specific unique and easily identifiable populations...
  14. ncbi Efficacy and durability of nevirapine in antiretroviral-experienced patients
    Marianne Harris
    B C Centre for Excellence in HIV AIDS and the Canadian HIV Trials Network, St Paul s Hospital, Providence Health Care, University of British Columbia, 1081 Burrard Street, Vancouver, V6Z 1Y6, Canada
    J Acquir Immune Defic Syndr 34:S53-8. 2003
    ..This paper reviews the clinical data that support the use of NVP in salvage regimens and PI switch strategies...
  15. ncbi Hepatotoxicity of nucleoside reverse transcriptase inhibitors
    Valentina Montessori
    Clinical Assistant Professor, University of British Columbia, Vancouver, Canada
    Semin Liver Dis 23:167-72. 2003
    ..Early recognition and intervention are essential to avert serious outcomes...
  16. ncbi Prevalence of bone mineral density abnormalities and related risk factors in an ambulatory HIV clinic population
    Silvia Guillemi
    British Columbia Centre for Excellence in HIV AIDS, Vancouver, British Columbia, Canada
    J Clin Densitom 13:456-61. 2010
    ..Lower BMI was independently associated with low BMD. No correlation was found between abnormal BMD and cumulative exposure to any antiretroviral agents...
  17. ncbi Case series assessing the safety of mycophenolate as part of multidrug rescue treatment regimens
    Natasha Press
    British Columbia Centre for Excellence in HIV AIDS, St Paul s Hospital and Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada
    HIV Clin Trials 3:17-20. 2002
    ..By potentiating the activity of abacavir, MMF may improve antiviral efficacy. However, it may also lead to myelosuppression, such as was seen in patients taking hydroxyurea-containing regimens...
  18. ncbi Factors associated with virological suppression among HIV-positive individuals on highly active antiretroviral therapy in a multi-site Canadian cohort
    A M Cescon
    British Columbia Centre for Excellence in HIV AIDS, Vancouver, Canada
    HIV Med 12:352-60. 2011
    ..The aim of the study was to evaluate time to virological suppression in a cohort of individuals who started highly active antiretroviral therapy (HAART), and to explore the factors associated with suppression...
  19. ncbi Life-threatening reaction after first ever dose of abacavir in an HIV-1-infected patient
    Rafael de la Rosa
    AIDS 18:578-9. 2004
  20. ncbi Transient neuropathy after needle-free injection outside of recommended sites
    Marianne Harris
    AIDS 20:784-5. 2006
  21. ncbi Stopping antiretroviral therapy: easier said than done
    Mark Hull
    AIDS 21:1817-8. 2007
  22. ncbi Delavirdine increases drug exposure of ritonavir-boosted protease inhibitors
    Marianne Harris
    AIDS 16:798-9. 2002
  23. ncbi Intracellular carbovir triphosphate levels in patients taking abacavir once a day
    Marianne Harris
    AIDS 16:1196-7. 2002
  24. ncbi Consecutive rebounds in plasma viral load are associated with virological failure at 52 weeks among HIV-infected patients
    Janet M Raboud
    Department of Public Health Sciences and Division of Infectious Diseases, University Health Network, University of Toronto, Toronto, Ontario, Canada
    AIDS 16:1627-32. 2002
    ..Given their high risk of short-term virological failure, patients who present with consecutive detectable pVL measurements following complete suppression should be considered ideal candidates for intervention studies...
  25. ncbi Exacerbation of depression associated with starting raltegravir: a report of four cases
    Marianne Harris
    AIDS 22:1890-2. 2008
  26. ncbi Anaerobic threshold and random venous lactate levels among HIV-positive patients on antiretroviral therapy
    Alicja M Tesiorowski
    J Acquir Immune Defic Syndr 31:250-1. 2002
  27. ncbi Influence of human papillomavirus type 16 (HPV-16) E2 polymorphism on quantification of HPV-16 episomal and integrated DNA in cervicovaginal lavages from women with cervical intraepithelial neoplasia
    Naoufel Azizi
    Laboratoire de Virologie Moleculaire, Centre de recherche du Centre Hospitalier de l Universite de Montreal, Montreal, Quebec, Canada
    J Gen Virol 89:1716-28. 2008
    ..24) or CIN-1 (5 of 14, P=0.50). HPV-16 E2 polymorphism was a significant factor that influenced measures of HPV-16 integrated viral load...
  28. ncbi Random venous lactate levels among HIV-positive patients on antiretroviral therapy
    Marianne Harris
    J Acquir Immune Defic Syndr 31:448-50. 2002
  29. ncbi Venous and arterial blood lactate in HIV-infected patients
    Carlos Zala
    Antivir Ther 7:309-10. 2002
  30. ncbi Adverse effects of antiretroviral therapy for HIV infection
    Valentina Montessori
    British Columbia Centre for Excellence in HIV/AIDS, Vancouver, BC
    CMAJ 170:229-38. 2004
    ..A better understanding of the adverse effects of antiretroviral agents is of interest not only for HIV specialists as they try to optimize therapy, but also for other physicians who care for HIV-positive patients...
  31. ncbi Structured treatment interruptions: a risky business
    Julio Montaner
    Clin Infect Dis 40:601-3. 2005